{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:55:58Z","timestamp":1771786558838,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T00:00:00Z","timestamp":1556064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.critrevonc.2019.03.016","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T12:27:13Z","timestamp":1553862433000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management"],"prefix":"10.1016","volume":"138","author":[{"given":"Anna","family":"Sureda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Domingo-Domenech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2019.03.016_bib0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/annonc\/mdi023","article-title":"A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly)","volume":"16","author":"Ballova","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0015","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/annonc\/mdl397","article-title":"ABVD for Hodgkin\u2019s lymphoma: full-dose chemotherapy without dose reductions or growth factors","volume":"18","author":"Boleti","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0020","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2015.64.5648","article-title":"Eight cycles of ABVD versus four cycles of BEACOPPescalated plus four cycles of BEACOPPbaseline in stage III to IV, international prognostic score >\/= 3, high-risk hodgkin lymphoma: first results of the phase III EORTC 20012 intergroup trial","volume":"34","author":"Carde","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0025","first-page":"184","article-title":"Intensified ChlVPP\/ABVVP chemotherapy regimen and pegfilgrastim support in advanced Hodgkin lymphoma","volume":"4","author":"Cocorocchio","year":"2010","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0030","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1182\/blood-2017-05-784678","article-title":"Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma","volume":"130","author":"Connors","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0035","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0040","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1200\/JCO.1998.16.12.3810","article-title":"BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP\/ABVD in patients with advanced-stage Hodgkin\u2019s lymphoma: interim report from a trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"16","author":"Diehl","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0045","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0050","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3111\/13696998.2013.782034","article-title":"A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia","volume":"16","author":"Dulisse","year":"2013","journal-title":"J. Med. Econ."},{"issue":"Suppl. 3","key":"10.1016\/j.critrevonc.2019.03.016_bib0055","doi-asserted-by":"crossref","first-page":"iii70","DOI":"10.1093\/annonc\/mdu181","article-title":"Hodgkin\u2019s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Eichenauer","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0060","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2015.64.8683","article-title":"ABVD or BEACOPP for advanced hodgkin lymphoma","volume":"34","author":"Engert","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0065","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2141.2007.06598.x","article-title":"G-CSF is not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis","volume":"137","author":"Evens","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0070","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.12222","article-title":"The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496","volume":"161","author":"Evens","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0075","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1200\/JCO.2008.17.0910","article-title":"ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin\u2019s lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0080","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1093\/annonc\/mdr385","article-title":"Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis","volume":"23","author":"Fossa","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0085","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0090","doi-asserted-by":"crossref","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","article-title":"Management of febrile neutropaenia: ESMO clinical practice guidelines","volume":"27","author":"Klastersky","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0095","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","article-title":"Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review","volume":"25","author":"Kuderer","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0100","first-page":"99","article-title":"Impact of chemotherapy dose intensity on cancer patient outcomes","volume":"7","author":"Lyman","year":"2009","journal-title":"J. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3816\/SCT.2003.n.002","article-title":"Epidemiology of febrile neutropenia","volume":"1","author":"Lyman","year":"2003","journal-title":"Support. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0110","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0115","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdn655","article-title":"A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies","volume":"20","author":"Moreau","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0125","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hematopoietic Growth Factors V.2.2019 \u00a9 National Comprehensive Cancer Network, Inc. 2019a. All rights reserved. Accessed March 26, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0130","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hodgkin Lymphoma V.1.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019b. All rights reserved. Accessed March 26, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0135","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prevention and Treatment of Cancer-Related Infections V.1.2019. \u00a9 National Comprehensive Cancer Network, Inc. 2019c. All rights reserved. Accessed March 26, 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0140","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/S0959-8049(03)00662-2","article-title":"EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer","volume":"39","author":"Repetto","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0145","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/bjh.12862","article-title":"A phase II study of dose-dense and dose-intense ABVD (ABVDDD-DI) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma","volume":"166","author":"Russo","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-3-27","article-title":"Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery","volume":"3","author":"Schwenkglenks","year":"2010","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0155","first-page":"15","article-title":"Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin\u2019s lymphoma treated with chemotherapy","volume":"9","author":"Scott","year":"2003","journal-title":"J. Manag. Care Pharm."},{"issue":"24","key":"10.1016\/j.critrevonc.2019.03.016_bib0160","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline","volume":"2006","author":"Smith","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0165","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0170","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/bjh.13419","article-title":"Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly","volume":"170","author":"Stamatoullas","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7534","article-title":"Improving outcomes with brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma","volume":"36","author":"Straus","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0180","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s11596-014-1268-2","article-title":"Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin\u2019s lymphoma: a retrospective analysis","volume":"34","author":"Tao","year":"2014","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0185","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin\u2019s lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0190","first-page":"3131","article-title":"The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"23","author":"Wang","year":"2015","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0195","first-page":"979","article-title":"Importance of risk factors for febrile neutropenia among patients receiving chemotherapy regimens not classified as high-risk in guidelines for myeloid growth factor use","volume":"13","author":"Weycker","year":"2015","journal-title":"J. Compr. Canc. Netw."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0200","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1182\/blood-2012-01-405456","article-title":"Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma","volume":"119","author":"Younes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0205","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2019.03.016_bib0210","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818301379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T19:27:32Z","timestamp":1760902052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818301379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":42,"alternative-id":["S1040842818301379"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.016","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neutropenia during frontline treatment of advanced Hodgkin lymphoma: Incidence, risk factors, and management","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2019.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}